AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24703722
Drug: Itolizumab arm
RxNorm normalized name: ibalizumab
DrugBank: Ibalizumab (DB12698)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Itolizumab arm B (1.6 mg/kg every 2 weeks)
Trial: 24703722
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment arms (A, B, placebo)
Trial: 19775046
Drug: Propofol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1.5 mg/kg (Group IB)
Trial: 9517944
Drug: Clarithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (500 mg every 12 h)
Trial: 16892732
Drug: Prednisolone (30mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (30mg once daily in the morning)
Trial: 16892732
Drug: Sustained-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release theophylline (600-800mg per day in b.i.d. dosage)
Trial: 2195106
Drug: Branched chain
RxNorm normalized name: Branched Chain Amino Acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branched chain enriched amino acid mixture (1 g/kg per day)
Trial: 2195106
Drug: Isocaloric glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric glucose infusion
Trial: 7377640
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release theophylline tablets
Trial: 7377640
Drug: Short acting
RxNorm normalized name: Prolixin (short acting injection) 2.5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short acting theophylline tablets
Trial: 15347709
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy (control)
Trial: 15871754
Drug: Noninvasive positive-pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noninvasive positive-pressure ventilation (NPPV) daily for 3 days for intervals of 8, 6, and 4 hours, plus standard therapy
Trial: 10487134
Drug: 0.6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/kg rocuronium (Group I)
Trial: 10487134
Drug: 0.015 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.015 mg/kg pancuronium (Group II)
Trial: 10487134
Drug: 0.06 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.06 mg/kg rocuronium (Group III)
Trial: 18642635
Drug: Constraint-Induced Movement
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint-Induced Movement Therapy (CIMT)
Trial: 23265995
Drug: Amoxicillin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (1 g three times daily for 7 days)
Trial: 19318384
Drug: Intensive glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glucose control (target blood glucose range of 81 to 108 mg/dL)
Trial: 19318384
Drug: Conventional glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional glucose control (target blood glucose of 180 mg/dL or less)
Trial: 15270803
Drug: Pulsed-dose electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulsed-dose electrical stimulation (50 micro amps) through silver-plated nylon-dacron stocking electrodes for 8 hours a night for 6 weeks
Trial: 11772239
Drug: Novel treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel treatments targeting specific steps in the disease process, including mycophenolate mofetil and adenosine analogues.
Trial: 11772239
Drug: Immunoablative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoablative chemotherapy with or without haematopoietic stem cell rescue.
Trial: 11772239
Drug: Blocking co-stimulatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blocking co-stimulatory molecules (e.g., CD40 ligand, CTLA4-Ig).
Trial: 29245244
Drug: Joint mobilization
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Joint mobilization manipulation treatment once a day and regular training twice a day for a month
Trial: 8513655
Drug: Naringin solution
RxNorm normalized name: Naringin
DrugBank: Naringin (DB16859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naringin solution
Trial: 3318546
Drug: Etomidate (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate (0.3 mg/kg)
Trial: 20829648
Drug: Imagery Rehearsal
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imagery Rehearsal Therapy (IRT)
Trial: 23725518
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg/day for 6 months
Trial: 16184258
Drug: Sibutramine 10
RxNorm normalized name: sibutramine 10 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine 10 mg
Trial: 17000360
Drug: Adenosine (0.14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (0.14 mg/kg/min continuous infusion over 2 minutes)
Trial: 26176644
Drug: Both adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Both adalimumab preparations
Trial: 21718265
Drug: Once-weekly resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly resistance training
Trial: 12117873
Drug: Polymeric enteral
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymeric enteral diet (PEN1) containing 35 g of lipids per 1000 kcal, high in oleate (79%) and low in linoleate (6.5%)
Trial: 2752179
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone (1 mg/kg/day)
Trial: 2109766
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy on urinary incontinence
Trial: 11500583
Drug: Intravenous ajmaline
RxNorm normalized name: ajmaline
DrugBank: Ajmaline (DB01426)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ajmaline
Trial: 12022585
Drug: Amiodarone therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone therapy
Trial: 14534370
Drug: Ginger root
RxNorm normalized name: Ginger Root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger root (1 g)
Trial: 11761012
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg omeprazole for 7 days
Trial: 10972172
Drug: No omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No omeprazole treatment (Control)
Trial: 1616162
Drug: Meperidine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (1.5 mg/kg)
Trial: 3915058
Drug: Diclofensine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofensine 15 mg
Trial: 3915058
Drug: Diclofensine 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofensine 25 mg
Trial: 25899452
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg daily
Trial: 8722350
Drug: G-CSF administration
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF administration on day 1 after transplantation (group 1)
Trial: 6362846
Drug: Single IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV infusion of killed C. parvum vaccine
Trial: 31201197
Drug: TRAM/paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRAM/paracetamol
Trial: 23020253
Drug: SAXA-MET (saxagliptin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAXA-MET (saxagliptin 5 mg/day added to metformin 1500 mg/day)
Trial: 23020253
Drug: MET-UP (metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MET-UP (metformin uptitration to a maximum dose of 2500 mg/day)
Trial: 17905274
Drug: Isoflurane treatment
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoflurane treatment (0.5 MAC)
Trial: 17905274
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no isoflurane treatment)
Trial: 14996603
Drug: L-arginine and
RxNorm normalized name: Amino Acid, Amino Acids 5% (L-Arginine and L-Lysine) intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine and vitamin C infusion
Trial: 12135314
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C infusion
Trial: 2563314
Drug: Esmolol 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol 80 mg I.V. bolus followed by 12 mg/min infusion
Trial: 31733088
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine 0.2 mg/kg
Trial: 23563904
Drug: Standard-of-care (SoC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care (SoC) treatment
Trial: 20088412
Drug: Intravenous drip
RxNorm normalized name: DRIP COLLECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous drip of Granisetron only
Trial: 15716033
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with prolonged medical treatment for intractable epilepsy
Trial: 9119715
Drug: Cold therapy
RxNorm normalized name: Deep Cold Therapy
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold therapy (ice pack placed on injection site for 15 min prior to injection)
Trial: 9119715
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (injections according to hospital protocol)
Trial: 31630504
Drug: Perifascial technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perifascial technique (20 mL of 10 mg/mL mepivacaine along the latissimus dorsi and superficial axillary fascia)
Trial: 31630504
Drug: Perineural technique
RxNorm normalized name: ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perineural technique (20 mL of 10 mg/mL mepivacaine around radial, median, ulnar and musculocutaneous nerves)
Trial: 9705161
Drug: Capsaicin 0.05%
RxNorm normalized name: CAPSAICIN 0.05% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsaicin 0.05% applied three times daily for 5 days
Trial: 8537137
Drug: Cefixime suspension
RxNorm normalized name: Cefixime
DrugBank: Cefixime (DB00671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefixime suspension (8 mg/kg/day, b.i.d., for 10 days)
Trial: 8537137
Drug: Amoxicillin-clavulanate suspension
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanate suspension (80 mg/kg/day, t.i.d., for 10 days)
Trial: 2233283
Drug: Aspartame in
RxNorm normalized name: Aspartame
DrugBank: Aspartame (DB00168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame in capsules (20 mg/kg)
Trial: 28197849
Drug: Myofascial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myofascial therapy in addition to a standard physical therapy program
Trial: 28197849
Drug: Placebo intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intervention in addition to a standard physical therapy program
Trial: 28197849
Drug: Standard physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard physical therapy program (both groups)
Trial: 27124003
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate tablets from 2 different Chinese pharmaceutical manufacturers
Trial: 1489941
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate tablets
Trial: 17418968
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of melatonin in the morning (8-9 AM)
Trial: 17418968
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of melatonin in the evening (8-9 PM)
Trial: 16599071
Drug: Percutaneous coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous coronary intervention (PCI) with adjuvant therapy (glycoprotein IIB/IIIA receptor inhibitors and clopidogrel)
Trial: 1606457
Drug: Fibrinolytic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinolytic agents
Trial: 1978373
Drug: Benztropine (BZ)
DrugBank: Benzatropine (DB00245)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benztropine (BZ) at 2 mg i.m. and then 1 mg p.o. b.i.d. for 2 days
Trial: 25922463
Drug: Intermittent pneumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent pneumatic compression (IPC) therapy for six hours per day (n = 74)
Trial: 25922463
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual in a plaster cast without IPC (n = 74)
Trial: 25922463
Drug: Intermittent pneumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent pneumatic compression (IPC) therapy
Trial: 23528027
Drug: Glycoprotein IIb/IIIa
RxNorm normalized name: GLYCOPROTEIN IIB/IIIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoprotein IIb/IIIa inhibitors (GPIs) during TRA PCI
Trial: 21663617
Drug: Wet-cupping treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wet-cupping treatment
Trial: 15671702
Drug: Nonusers of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonusers of Hormone Replacement Therapy (HRT)
Trial: 9199952
Drug: Enoximone echocardiography
RxNorm normalized name: enoximone
DrugBank: Enoximone (DB04880)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone echocardiography (1 mg/kg over 5 min)
Trial: 8179735
Drug: Metoclopramide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (10 mg syrup)
Trial: 26256964
Drug: Triflusal (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triflusal (300 mg, b.i.d.)
Trial: 26256964
Drug: Aspirin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (150 mg, b.i.d.)
Trial: 15033211
Drug: Group cognitive-behavior
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive-behavior therapy (Group)
Trial: 8421475
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1000 mg per day)
Trial: 3321483
Drug: Ketamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.5 mg/kg intravenously before operation
Trial: 31702047
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g glucose
Trial: 12450897
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g glucose
Trial: 26902618
Drug: Pre-clipping injection
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-clipping injection group (PG)
Trial: 26902618
Drug: Conventional injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional injection group (CG)
Trial: 30664496
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (Control)
Trial: 23604336
Drug: Methylphenidate (40
RxNorm normalized name: methylphenidate (40/60 release) 15 mg/24 hr oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (40 mg)
Trial: 24094274
Drug: Psychological treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological treatments (specific types not detailed)
Trial: 19682661
Drug: Rivastigmine 3-12
RxNorm normalized name: rivastigmine 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine 3-12 mg/d capsules
Trial: 17430256
Drug: 0.1% captopril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% captopril gel
Trial: 17430256
Drug: 0.5% captopril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% captopril gel
Trial: 11160953
Drug: Lamotrigine 200
RxNorm normalized name: lamotrigine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine 200 mg/d
Trial: 11160953
Drug: Lamotrigine 25
RxNorm normalized name: lamotrigine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine 25 mg/d
Trial: 8310507
Drug: 33B3.1 monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 33B3.1 monoclonal antibody (10 mg/day)
Trial: 8310507
Drug: Rabbit antithymocyte
RxNorm normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabbit antithymocyte globulin (ATG) (1.5 mg/kg/day)
Trial: 8310507
Drug: 33B3.1 monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 33B3.1 monoclonal antibody
Trial: 29747597
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (six-weekly sessions of smoking cessation behavioural-support)
Trial: 19032914
Drug: Early use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers
Trial: 18249214
Drug: Initial fasting
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial fasting plasma glucose (FPG) values <100 mg/dL
Trial: 18249214
Drug: Initial fasting
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial fasting plasma glucose (FPG) values 100 to 109 mg/dL
Trial: 18249214
Drug: Initial fasting
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial fasting plasma glucose (FPG) values 110 to 125 mg/dL
Trial: 18249214
Drug: New definition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New definition of IFG including persons with FPG 100 to 109 mg/dL
Trial: 18249214
Drug: Fasting plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting plasma glucose levels from 64 to 125 mg/dL
Trial: 11420590
Drug: Intramuscular betamethasone
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular betamethasone 12 mg
Trial: 11420590
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone 50 mg daily for seven days
Trial: 9349933
Drug: Intravenous 6-mercaptopurine
RxNorm normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous 6-mercaptopurine (1 g.m-2: bolus dose of 0.2 g.m-2 followed by an 8-h infusion of 0.8 g.m-2)
Trial: 16204287
Drug: Agalsidase alfa
RxNorm normalized name: Agalsidase alfa
DrugBank: Agalsidase alfa (DB15874)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Agalsidase alfa (0.2 mg/kg) infused intravenously every other week for 4-4.5 years
Trial: 12555510
Drug: Naftidrofuryl 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftidrofuryl 200 mg tid
Trial: 8099978
Drug: Timing principle
RxNorm normalized name: Muguettine principle
DrugBank: Hydroxycitronellal (DB14187)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timing principle group (vecuronium 0.15 mg.kg‐1 followed by thiopental 5 mg.kg‐1, intubation 60 seconds after thiopental)
Trial: 18671864
Drug: Bright blue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright blue light therapy (BLT)
Trial: 27461
Drug: Vaccine administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine administered by aerosol route, three times a week for 5 weeks (Group I)
Trial: 27943546
Drug: Vildagliptin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin (50 mg once-daily or twice-daily)
Trial: 24015698
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bioactive food ingredients (capsaicinoids, epigallocatechin gallate, piperin, and l-carnitine)
Trial: 17094387
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (somatostatin analog octreotide 20 mg i.m. every 28 days + oral dexamethasone 4 mg daily for 1 month, reduced to 1 mg daily by the fourth month, with a 1 mg daily maintenance dose thereafter + zoledronate 4 mg i.v. every 4 weeks)
Trial: 9703407
Drug: Tepoxalin 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tepoxalin 50 mg twice daily for 3.5 days
Trial: 9703407
Drug: Tepoxalin 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tepoxalin 200 mg twice daily for 3.5 days
Trial: 2685180
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy multicenter trial
Trial: 30732996
Drug: Low-dose ferrous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ferrous sulfate (1-3 mg/kg/day)
Trial: 23793486
Drug: Self-administered (mailed)
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered (mailed) questionnaires